<DOC>
	<DOCNO>NCT02881008</DOCNO>
	<brief_summary>Randomized , open-label multicentre clinical trial daily Myrcludex B versus entecavir patient HBeAg negative chronic hepatitis B .</brief_summary>
	<brief_title>Clinical Trial Myrcludex B v Entecavir Patients With HBeAg Negative Chronic Hepatitis B</brief_title>
	<detailed_description>This randomize , open-label multicentre clinical trial daily Myrcludex B versus entecavir patient HBeAg negative chronic hepatitis B . Accounting screen-outs 76 patient screen 48 randomized 6 treatment group : Arm A ( 8 patient ) : Myrcludex B 0.5 mg / day / sc / 12 week Arm B ( 8 patient ) : Myrcludex B 1 mg / day / sc / 12 week Arm C ( 8 patient ) : Myrcludex B 2 mg / day / sc / 12 week Arm D ( 8 patient ) : Entecavir 0.5 mg / day / orally / 24 week Arm E ( 8 patient ) : Myrcludex B 5 mg / day / sc / 12 week Arm F ( 8 patient ) : Myrcludex B 10 mg / day / sc / 24 week The study consist screen period 28 day ( Day -28 -1 ) ; baseline visit ( Day 0 ) , treatment period 12 week group A-C , E 24 week group D , F ; follow-up period 12 week group A-C , E , F .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Age 1865 year inclusive time give write informed consent study participation . 2 . Chronic hepatitis B define presence HBsAg least 6 month prior screen period . 3 . Liver biopsy perform within one year prior screen screen period . 4 . Alanine aminotransferase ( ALT ) ≥1.5 x ULN ≤ 6 x ULN . If ALT level screen period ≥1 ULN patient include study obtain sponsor 's approval follow condition meet : evidence inflammation lymphocyte infiltration confirm liver biopsy perform within 6 month prior inclusion study , and/or patient history elevate ALT level ≥1.5 ULN 12 month prior screen period . 5 . HBeAg negative antiHBeAg positive . 6 . HBV DNA ≥ 104 copies/mL . 7 . All woman childbearing potential must negative urine pregnancy test prior enrolment . 8 . Women must : Be menopausal least 2 year , Be surgically sterile ( total hysterectomy bilateral ovariectomy bilateral tubal ligation/clips otherwise incapable pregnancy ) , Not heterosexually active study , Agree use highly effective method birth control ( double barrier method combination barrier method hormonal intrauterine device ) study 3 month last dosing investigational medicinal product . 9 . Men must agree use highly effective method birth control ( double barrier method combination barrier method hormonal intrauterine device womenpartner ) donate sperm study 3 month last dosing investigational medicinal product . 10 . An understanding , ability willingness fully comply study procedure restriction . 11 . An ability provide write informed consent participate study . 1 . Decompensated liver disease ( ChildPughScore &gt; 6 ) . 2 . Any sign liver cirrhosis ( histological , ultra sound , biochemical ) . 3 . Coinfected hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) , HIV . 4 . ALT &gt; 6 ULN . 5 . Creatinine clearance &lt; 60 mL/min . 6 . Total bilirubin &gt; 2 mg/dL . 7 . Pretreatment nucleosideanalogues ( lamivudine , telbivudine , entecavir ) less 6 month prior first dose investigational medicinal product . Pretreatment nucleotideanalogues interferon allow . 8 . History hepatocellular carcinoma ( HCC ) finding suggestive possible HCC , suspicious focus image study elevate serum alphafetoprotein ( AFP ) level . In patient finding , HCC ruledout prior screen present study . 9 . One additional know primary secondary cause liver disease , hepatitis B ( e.g. , alcoholism , autoimmune hepatitis , malignancy hepatic involvement , hemochromatosis , alpha1 antitrypsin deficiency , Wilson 's Disease , congenital metabolic condition affect liver , e.g . congestive heart failure severe cardiopulmonary disease ) . Patients Gilbert 's syndrome DubinJohnson syndrome , two benign disorder associate lowgrade hyperbilirubinemia enrol trial . 10 . History clinically evident pancreatitis . 11 . History alcohol drug abuse within precede two year . For purpose present study , alcohol abuse arbitrarily define frequent consumption alcoholic beverage average daily intake 40 g ethanol . 12 . Participation another study investigational drug within less one month prior study simultaneously study . 13 . Patients unable unwilling follow protocol requirement . 14 . Patients history seizure , central nervous system disorder psychiatric disability think clinically significant opinion investigator . 15 . Patients limited mental capacity extent she/he provide inform consent information regard adverse event study drug . 16 . Clinically significant renal , respiratory cardiovascular disease . 17 . Pregnancy lactation . 18 . Patients previously participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>